ID   STK10_HUMAN             Reviewed;         968 AA.
AC   O94804; A6ND35; B2R8F5; B3KMY1; Q6NSK0; Q9UIW4;
DT   24-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1999, sequence version 1.
DT   15-MAR-2017, entry version 167.
DE   RecName: Full=Serine/threonine-protein kinase 10;
DE            EC=2.7.11.1;
DE   AltName: Full=Lymphocyte-oriented kinase;
GN   Name=STK10; Synonyms=LOK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=10199912; DOI=10.1007/s002510050509;
RA   Kuramochi S., Matsuda Y., Okamoto M., Kitamura F., Yonekawa H.,
RA   Karasuyama H.;
RT   "Molecular cloning of the human gene STK10 encoding lymphocyte-
RT   oriented kinase, and comparative chromosomal mapping of the human,
RT   mouse, and rat homologues.";
RL   Immunogenetics 49:369-375(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Teratocarcinoma, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T.,
RA   Gomez M., Gonzales E., Goodstein D., Grigoriev I., Groza M.,
RA   Hammon N., Hawkins T., Haydu L., Israni S., Jett J., Kadner K.,
RA   Kimball H., Kobayashi A., Lopez F., Lou Y., Martinez D., Medina C.,
RA   Morgan J., Nandkeshwar R., Noonan J.P., Pitluck S., Pollard M.,
RA   Predki P., Priest J., Ramirez L., Retterer J., Rodriguez A.,
RA   Rogers S., Salamov A., Salazar A., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., Dickson M.,
RA   Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., Rokhsar D.S.,
RA   Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 814-968.
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [7]
RP   FUNCTION.
RX   PubMed=11903060; DOI=10.1042/0264-6021:3630175;
RA   Tao L., Wadsworth S., Mercer J., Mueller C., Lynn K., Siekierka J.,
RA   August A.;
RT   "Opposing roles of serine/threonine kinases MEKK1 and LOK in
RT   regulating the CD28 responsive element in T-cells.";
RL   Biochem. J. 363:175-182(2002).
RN   [8]
RP   FUNCTION, TISSUE SPECIFICITY, AND MUTAGENESIS OF LYS-65.
RX   PubMed=12639966; DOI=10.1074/jbc.M212556200;
RA   Walter S.A., Cutler R.E. Jr., Martinez R., Gishizky M., Hill R.J.;
RT   "Stk10, a new member of the polo-like kinase kinase family highly
RT   expressed in hematopoietic tissue.";
RL   J. Biol. Chem. 278:18221-18228(2003).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-438, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-438, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=T-cell;
RX   PubMed=19367720; DOI=10.1021/pr800500r;
RA   Carrascal M., Ovelleiro D., Casas V., Gay M., Abian J.;
RT   "Phosphorylation analysis of primary human T lymphocytes using
RT   sequential IMAC and titanium oxide enrichment.";
RL   J. Proteome Res. 7:5167-5176(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-438, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-191 AND SER-438, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-13; SER-191; SER-454 AND
RP   THR-952, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-191; SER-438 AND
RP   SER-549, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [16]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=19255442; DOI=10.1073/pnas.0805963106;
RA   Belkina N.V., Liu Y., Hao J.J., Karasuyama H., Shaw S.;
RT   "LOK is a major ERM kinase in resting lymphocytes and regulates
RT   cytoskeletal rearrangement through ERM phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:4707-4712(2009).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-438, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [20]
RP   ENZYME REGULATION.
RX   PubMed=21606217; DOI=10.1124/mol.110.070862;
RA   Yamamoto N., Honma M., Suzuki H.;
RT   "Off-target serine/threonine kinase 10 inhibition by erlotinib
RT   enhances lymphocytic activity leading to severe skin disorders.";
RL   Mol. Pharmacol. 80:466-475(2011).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-13; SER-438; SER-450 AND
RP   SER-514, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-485; SER-514 AND
RP   THR-952, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 18-317 IN COMPLEX WITH
RP   PYRROLE-INDOLINONE INHIBITOR, ENZYME REGULATION, AUTOPHOSPHORYLATION,
RP   CATALYTIC ACTIVITY, AND SUBUNIT.
RX   PubMed=18239682; DOI=10.1038/emboj.2008.8;
RA   Pike A.C., Rellos P., Niesen F.H., Turnbull A., Oliver A.W.,
RA   Parker S.A., Turk B.E., Pearl L.H., Knapp S.;
RT   "Activation segment dimerization: a mechanism for kinase
RT   autophosphorylation of non-consensus sites.";
RL   EMBO J. 27:704-714(2008).
RN   [25]
RP   VARIANT TGCT GLU-277.
RX   PubMed=16175573; DOI=10.1002/gcc.20265;
RA   Bignell G., Smith R., Hunter C., Stephens P., Davies H., Greenman C.,
RA   Teague J., Butler A., Edkins S., Stevens C., O'meara S., Parker A.,
RA   Avis T., Barthorpe S., Brackenbury L., Buck G., Clements J., Cole J.,
RA   Dicks E., Edwards K., Forbes S., Gorton M., Gray K., Halliday K.,
RA   Harrison R., Hills K., Hinton J., Jones D., Kosmidou V., Laman R.,
RA   Lugg R., Menzies A., Perry J., Petty R., Raine K., Shepherd R.,
RA   Small A., Solomon H., Stephens Y., Tofts C., Varian J., Webb A.,
RA   West S., Widaa S., Yates A., Gillis A.J.M., Stoop H.J.,
RA   van Gurp R.J.H.L.M., Oosterhuis J.W., Looijenga L.H.J., Futreal P.A.,
RA   Wooster R., Stratton M.R.;
RT   "Sequence analysis of the protein kinase gene family in human
RT   testicular germ-cell tumors of adolescents and adults.";
RL   Genes Chromosomes Cancer 45:42-46(2006).
RN   [26]
RP   VARIANTS [LARGE SCALE ANALYSIS] CYS-268; GLU-277; TRP-322; ILE-336;
RP   SER-467; THR-710; LEU-853; THR-905 AND TYR-947.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase involved in regulation
CC       of lymphocyte migration. Phosphorylates MSN, and possibly PLK1.
CC       Involved in regulation of lymphocyte migration by mediating
CC       phosphorylation of ERM proteins such as MSN. Acts as a negative
CC       regulator of MAP3K1/MEKK1. May also act as a cell cycle regulator
CC       by acting as a polo kinase kinase: mediates phosphorylation of
CC       PLK1 in vitro; however such data require additional evidences in
CC       vivo. {ECO:0000269|PubMed:11903060, ECO:0000269|PubMed:12639966,
CC       ECO:0000269|PubMed:19255442}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:18239682}.
CC   -!- ENZYME REGULATION: Inhibited by the pyrrole-indolinone inhibitor
CC       SU11274 (K00593): intercalates between the ATP-binding Lys-65 and
CC       alpha-C glutamate (Glu-81), resulting in a partial disordering of
CC       the lysine side chain. Also specifically inhibited by erlotinib.
CC       Slightly inhibited by gefitinib. {ECO:0000269|PubMed:18239682,
CC       ECO:0000269|PubMed:21606217}.
CC   -!- SUBUNIT: Homodimer; homodimerization is required for activation
CC       segment autophosphorylation. {ECO:0000269|PubMed:18239682}.
CC   -!- INTERACTION:
CC       Self; NbExp=3; IntAct=EBI-3951541, EBI-3951541;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:19255442};
CC       Peripheral membrane protein {ECO:0000269|PubMed:19255442}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in rapidly proliferating
CC       tissues (spleen, placenta, and peripheral blood leukocytes). Also
CC       expressed in brain, heart, skeletal muscle, colon, thymus, kidney,
CC       liver, small intestine and lung. {ECO:0000269|PubMed:12639966}.
CC   -!- PTM: Autophosphorylates following homodimerization, leading to
CC       activation of the protein.
CC   -!- DISEASE: Testicular germ cell tumor (TGCT) [MIM:273300]: A common
CC       malignancy in males representing 95% of all testicular neoplasms.
CC       TGCTs have various pathologic subtypes including: unclassified
CC       intratubular germ cell neoplasia, seminoma (including cases with
CC       syncytiotrophoblastic cells), spermatocytic seminoma, embryonal
CC       carcinoma, yolk sac tumor, choriocarcinoma, and teratoma.
CC       {ECO:0000269|PubMed:16175573}. Note=The disease may be caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Inhibition by erlotinib, an orally administered
CC       EGFR tyrosine kinase inhibitor used for treatment, enhances STK10-
CC       dependent lymphocytic responses, possibly leading to the
CC       aggravation of skin inflammation observed upon treatment by
CC       erlotinib. {ECO:0000305|PubMed:21606217}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. STE20 subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAG51143.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB015718; BAA35073.1; -; mRNA.
DR   EMBL; AK022960; BAG51143.1; ALT_INIT; mRNA.
DR   EMBL; AK313350; BAG36152.1; -; mRNA.
DR   EMBL; AC024561; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471062; EAW61439.1; -; Genomic_DNA.
DR   EMBL; BC070077; AAH70077.1; -; mRNA.
DR   EMBL; AL133081; CAB61400.1; -; mRNA.
DR   CCDS; CCDS34290.1; -.
DR   PIR; T42687; T42687.
DR   RefSeq; NP_005981.3; NM_005990.3.
DR   UniGene; Hs.744005; -.
DR   PDB; 2J7T; X-ray; 2.00 A; A=18-317.
DR   PDB; 4AOT; X-ray; 2.33 A; A/B=18-317.
DR   PDB; 4BC6; X-ray; 2.20 A; A=24-316.
DR   PDB; 4EQU; X-ray; 2.00 A; A/B=18-317.
DR   PDB; 4USD; X-ray; 3.05 A; A/B=18-317.
DR   PDB; 4USE; X-ray; 2.65 A; A/B=18-317.
DR   PDB; 5AJQ; X-ray; 2.20 A; A/B=21-313.
DR   PDBsum; 2J7T; -.
DR   PDBsum; 4AOT; -.
DR   PDBsum; 4BC6; -.
DR   PDBsum; 4EQU; -.
DR   PDBsum; 4USD; -.
DR   PDBsum; 4USE; -.
DR   PDBsum; 5AJQ; -.
DR   ProteinModelPortal; O94804; -.
DR   SMR; O94804; -.
DR   BioGrid; 112669; 7.
DR   IntAct; O94804; 1.
DR   STRING; 9606.ENSP00000176763; -.
DR   BindingDB; O94804; -.
DR   ChEMBL; CHEMBL3981; -.
DR   GuidetoPHARMACOLOGY; 2211; -.
DR   iPTMnet; O94804; -.
DR   PhosphoSitePlus; O94804; -.
DR   BioMuta; STK10; -.
DR   EPD; O94804; -.
DR   MaxQB; O94804; -.
DR   PaxDb; O94804; -.
DR   PeptideAtlas; O94804; -.
DR   PRIDE; O94804; -.
DR   DNASU; 6793; -.
DR   Ensembl; ENST00000176763; ENSP00000176763; ENSG00000072786.
DR   GeneID; 6793; -.
DR   KEGG; hsa:6793; -.
DR   UCSC; uc003mbo.2; human.
DR   CTD; 6793; -.
DR   DisGeNET; 6793; -.
DR   GeneCards; STK10; -.
DR   HGNC; HGNC:11388; STK10.
DR   HPA; CAB020840; -.
DR   HPA; HPA015083; -.
DR   MalaCards; STK10; -.
DR   MIM; 273300; phenotype.
DR   MIM; 603919; gene.
DR   neXtProt; NX_O94804; -.
DR   OpenTargets; ENSG00000072786; -.
DR   PharmGKB; PA36197; -.
DR   eggNOG; KOG0579; Eukaryota.
DR   eggNOG; ENOG410XPQN; LUCA.
DR   GeneTree; ENSGT00810000125351; -.
DR   HOGENOM; HOG000236268; -.
DR   HOVERGEN; HBG052712; -.
DR   InParanoid; O94804; -.
DR   KO; K08837; -.
DR   OMA; SEEAECP; -.
DR   OrthoDB; EOG091G01Y1; -.
DR   PhylomeDB; O94804; -.
DR   TreeFam; TF351445; -.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   SignaLink; O94804; -.
DR   SIGNOR; O94804; -.
DR   ChiTaRS; STK10; human.
DR   EvolutionaryTrace; O94804; -.
DR   GeneWiki; STK10; -.
DR   GenomeRNAi; 6793; -.
DR   PRO; PR:O94804; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; ENSG00000072786; -.
DR   CleanEx; HS_STK10; -.
DR   ExpressionAtlas; O94804; baseline and differential.
DR   Genevisible; O94804; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0035579; C:specific granule membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0042801; F:polo kinase kinase activity; TAS:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0071593; P:lymphocyte aggregation; IEA:Ensembl.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:2000401; P:regulation of lymphocyte migration; IMP:UniProtKB.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR022165; PKK.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF12474; PKK; 2.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell cycle; Cell membrane; Coiled coil;
KW   Complete proteome; Kinase; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN         1    968       Serine/threonine-protein kinase 10.
FT                                /FTId=PRO_0000086697.
FT   DOMAIN       36    294       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      42     50       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      175    224       Activation segment.
FT   COILED      573    947       {ECO:0000255}.
FT   COMPBIAS    750    884       Gln-rich.
FT   ACT_SITE    157    157       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      65     65       ATP. {ECO:0000305}.
FT   BINDING     111    111       Inhibitor.
FT   BINDING     113    113       Inhibitor.
FT   BINDING     117    117       Inhibitor; via amide nitrogen.
FT   BINDING     175    175       Inhibitor.
FT   MOD_RES      13     13       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      20     20       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:E9PTG8}.
FT   MOD_RES     191    191       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES     438    438       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:18088087,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19367720,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     450    450       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     454    454       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     485    485       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     514    514       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     549    549       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     952    952       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:24275569}.
FT   VARIANT     268    268       R -> C (in dbSNP:rs35826078).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041131.
FT   VARIANT     277    277       K -> E (in TGCT; somatic mutation;
FT                                dbSNP:rs757545210).
FT                                {ECO:0000269|PubMed:16175573,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_023827.
FT   VARIANT     322    322       R -> W (in dbSNP:rs56214442).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041132.
FT   VARIANT     336    336       T -> I (in dbSNP:rs55972616).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041133.
FT   VARIANT     467    467       N -> S (in dbSNP:rs56063773).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041134.
FT   VARIANT     480    480       P -> L (in dbSNP:rs34505340).
FT                                /FTId=VAR_051671.
FT   VARIANT     520    520       P -> L (in dbSNP:rs17074311).
FT                                /FTId=VAR_051672.
FT   VARIANT     710    710       M -> T (in dbSNP:rs34936670).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041135.
FT   VARIANT     853    853       S -> L (in dbSNP:rs56066852).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041136.
FT   VARIANT     905    905       S -> T (in dbSNP:rs55791916).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041137.
FT   VARIANT     942    942       S -> N (in dbSNP:rs1128204).
FT                                /FTId=VAR_051673.
FT   VARIANT     947    947       C -> Y (in dbSNP:rs56355550).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041138.
FT   MUTAGEN      65     65       K->I: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:12639966}.
FT   CONFLICT     62     62       A -> V (in Ref. 5; AAH70077).
FT                                {ECO:0000305}.
FT   CONFLICT    136    136       V -> E (in Ref. 5; AAH70077).
FT                                {ECO:0000305}.
FT   CONFLICT    317    317       E -> G (in Ref. 5; AAH70077).
FT                                {ECO:0000305}.
FT   STRAND       27     30       {ECO:0000244|PDB:2J7T}.
FT   HELIX        32     34       {ECO:0000244|PDB:2J7T}.
FT   STRAND       36     43       {ECO:0000244|PDB:2J7T}.
FT   STRAND       45     47       {ECO:0000244|PDB:4USE}.
FT   STRAND       50     55       {ECO:0000244|PDB:2J7T}.
FT   TURN         56     58       {ECO:0000244|PDB:2J7T}.
FT   STRAND       61     67       {ECO:0000244|PDB:2J7T}.
FT   HELIX        75     87       {ECO:0000244|PDB:2J7T}.
FT   STRAND       96    101       {ECO:0000244|PDB:2J7T}.
FT   STRAND      106    111       {ECO:0000244|PDB:2J7T}.
FT   HELIX       118    125       {ECO:0000244|PDB:2J7T}.
FT   HELIX       131    150       {ECO:0000244|PDB:2J7T}.
FT   HELIX       160    162       {ECO:0000244|PDB:2J7T}.
FT   STRAND      163    165       {ECO:0000244|PDB:2J7T}.
FT   STRAND      171    173       {ECO:0000244|PDB:2J7T}.
FT   HELIX       177    187       {ECO:0000244|PDB:2J7T}.
FT   HELIX       196    198       {ECO:0000244|PDB:2J7T}.
FT   HELIX       201    208       {ECO:0000244|PDB:2J7T}.
FT   TURN        212    216       {ECO:0000244|PDB:2J7T}.
FT   HELIX       217    232       {ECO:0000244|PDB:2J7T}.
FT   TURN        236    239       {ECO:0000244|PDB:2J7T}.
FT   HELIX       242    251       {ECO:0000244|PDB:2J7T}.
FT   HELIX       260    262       {ECO:0000244|PDB:2J7T}.
FT   HELIX       265    274       {ECO:0000244|PDB:2J7T}.
FT   TURN        279    281       {ECO:0000244|PDB:2J7T}.
FT   HELIX       285    288       {ECO:0000244|PDB:2J7T}.
FT   TURN        292    296       {ECO:0000244|PDB:2J7T}.
FT   HELIX       301    314       {ECO:0000244|PDB:2J7T}.
SQ   SEQUENCE   968 AA;  112135 MW;  15E245193ECC553D CRC64;
     MAFANFRRIL RLSTFEKRKS REYEHVRRDL DPNEVWEIVG ELGDGAFGKV YKAKNKETGA
     LAAAKVIETK SEEELEDYIV EIEILATCDH PYIVKLLGAY YHDGKLWIMI EFCPGGAVDA
     IMLELDRGLT EPQIQVVCRQ MLEALNFLHS KRIIHRDLKA GNVLMTLEGD IRLADFGVSA
     KNLKTLQKRD SFIGTPYWMA PEVVMCETMK DTPYDYKADI WSLGITLIEM AQIEPPHHEL
     NPMRVLLKIA KSDPPTLLTP SKWSVEFRDF LKIALDKNPE TRPSAAQLLE HPFVSSITSN
     KALRELVAEA KAEVMEEIED GRDEGEEEDA VDAASTLENH TQNSSEVSPP SLNADKPLEE
     SPSTPLAPSQ SQDSVNEPCS QPSGDRSLQT TSPPVVAPGN ENGLAVPVPL RKSRPVSMDA
     RIQVAQEKQV AEQGGDLSPA ANRSQKASQS RPNSSALETL GGEKLANGSL EPPAQAAPGP
     SKRDSDCSSL CTSESMDYGT NLSTDLSLNK EMGSLSIKDP KLYKKTLKRT RKFVVDGVEV
     SITTSKIISE DEKKDEEMRF LRRQELRELR LLQKEEHRNQ TQLSNKHELQ LEQMHKRFEQ
     EINAKKKFFD TELENLERQQ KQQVEKMEQD HAVRRREEAR RIRLEQDRDY TRFQEQLKLM
     KKEVKNEVEK LPRQQRKESM KQKMEEHTQK KQLLDRDFVA KQKEDLELAM KRLTTDNRRE
     ICDKERECLM KKQELLRDRE AALWEMEEHQ LQERHQLVKQ QLKDQYFLQR HELLRKHEKE
     REQMQRYNQR MIEQLKVRQQ QEKARLPKIQ RSEGKTRMAM YKKSLHINGG GSAAEQREKI
     KQFSQQEEKR QKSERLQQQQ KHENQMRDML AQCESNMSEL QQLQNEKCHL LVEHETQKLK
     ALDESHNQNL KEWRDKLRPR KKALEEDLNQ KKREQEMFFK LSEEAECPNP STPSKAAKFF
     PYSSADAS
//
